cell therapy Archives -

Gilead’s Kite takes control of CAR-T partner Tmunity

Phil Taylor CAR-T therapy, cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, M&A, Oncology, Tmunity 0 Comment

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to

Gilead’s Kite takes control of CAR-T partner Tmunity

https://pharmaphorum.com/news/gileads-kite-takes-control-of-car-t-partner-tmunity/

Market Access/ News/ News/ News/ Oncology

Atara claims first world approval for off-the-shelf T-cell therapy

Phil Taylor allogeneic, Atara Biotherapeutics, cell therapy, Ebvallo, rare disease 0 Comment

Atara Biotherapeutics has become the first biotech to win regulatory approval for a T-cell therapy based on donated

Atara claims first world approval for off-the-shelf T-cell therapy

https://pharmaphorum.com/news/atara-claims-first-world-approval-for-off-the-shelf-t-cell-therapy/

News/ News/ News/ Oncology/ R&D

GSK’s pullback from cell therapy continues as Immatics alliance ends

Phil Taylor cell therapy, GlaxoSmithKline, Immatics, immuno-oncology, Oncology, partnering, TCR 0 Comment

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see

GSK’s pullback from cell therapy continues as Immatics alliance ends

https://pharmaphorum.com/news/gsks-pullback-from-cell-therapy-continues-as-immatics-alliance-ends/

Market Access/ News/ News/ News/ Oncology

Atara closes on first approval of transplant complication therapy

Phil Taylor allogeneic, Atara Biotherapeutics, cell therapy, Ebvallo, immuno-oncology, Oncology, Pierre Fabre, tabelecleucel 0 Comment

Atara Biotherapeutics’ cell therapy Ebvallo should be approved to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), according

Atara closes on first approval of transplant complication therapy

https://pharmaphorum.com/news/atara-closes-on-first-approval-of-transplant-complication-therapy/

News/ News/ Oncology

Roche puts $70m into ArsenalBio’s programmable T-cell platform

Phil Taylor ArsenalBio, cell therapy, Genentech, immuno-oncology, Oncology, partnering, Roche, solid tumours 0 Comment

Roche’s Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech’s

Roche puts $70m into ArsenalBio’s programmable T-cell platform

https://pharmaphorum.com/news/roche-puts-70m-into-arsenalbios-programmable-t-cell-platform/

Preparing for an influx of cell and gene therapy approvals

News/ News/ Press Releases/ R&D

CapstanTx secures $165 million to deliver precise in vivo cell engineering

Nicole Raleigh Capstan Therapeutics, CAR-T therapy, cell therapy, in vivo, investment, Lipid Nanoparticles, mRNA, pharma, tLNP 0 Comment

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it

CapstanTx secures $165 million to deliver precise in vivo cell engineering

https://pharmaphorum.com/news/capstantx-secures-165-million-to-deliver-precise-in-vivo-cell-engineering/

News/ News/ Oncology

ESMO: TIL therapy improves on Yervoy in melanoma trial

Phil Taylor cell therapy, ESMO 2022, immuno-oncology, melanoma, Oncology, tumour-infiltrating lymphocytes 0 Comment

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at

ESMO: TIL therapy improves on Yervoy in melanoma trial

https://pharmaphorum.com/news/esmo-til-therapy-improves-on-yervoy-in-melanoma-trial/

iPSC Pharma Phorum banner (1422 × 800 px)

Market Access/ Partner content/ Press releases

2nd iPSC-Derived Cell Therapies Summit

jade faulkner Allogenic, cell therapy, iPSC, Regenerative medicine, stem cell 0 Comment

The Industry’s Largest Event Showcasing iPSC Therapies

2nd iPSC-Derived Cell Therapies Summit

https://pharmaphorum.com/partner-content/2nd-ipsc-derived-cell-therapies-summit/

News/ News/ R&D

Vertex buys diabetes cell therapy rival ViaCyte for $320m

Phil Taylor cell therapy, M&A, type 1 diabetes, Vertex Pharma, ViaCyte 0 Comment

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million

Vertex buys diabetes cell therapy rival ViaCyte for $320m

https://pharmaphorum.com/news/vertex-buys-diabetes-cell-therapy-rival-viacyte-for-320m/

Trending

cell therapy

Login